ABVC Biopharma Files 8-K on Financials

TL;DR

ABVC Bio filed an 8-K on March 14th detailing financial results. Check it for the latest on their operations.

AI Summary

ABVC Biopharma, Inc. filed an 8-K on March 14, 2024, reporting on its financial condition and results of operations. The filing details the company's status and provides information related to its financial statements and exhibits.

Why It Matters

This filing provides crucial updates on ABVC Biopharma's financial health and operational performance, which is essential for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful review by investors.

Key Players & Entities

• ABVC BIOPHARMA, INC. (company) — Registrant
• March 14, 2024 (date) — Filing Date
• 44370 Old Warm Springs Blvd. (address) — Company Business Address
• Fremont, CA (location) — Company City and State
• 94538 (zip_code) — Company Zip Code

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar

Filing Documents

• ea0201766-8k_abvcbio.htm (8-K) — 27KB
• ea020176601ex99-1_abvcbio.htm (EX-99.1) — 118KB
• ex99-1_001.jpg (GRAPHIC) — 6KB
• 0001213900-24-022396.txt ( ) — 340KB
• abvc-20240314.xsd (EX-101.SCH) — 3KB
• abvc-20240314_lab.xml (EX-101.LAB) — 33KB
• abvc-20240314_pre.xml (EX-101.PRE) — 22KB
• ea0201766-8k_abvcbio_htm.xml (XML) — 3KB

02 Results of Operations and Financial

Item 2.02 Results of Operations and Financial Condition. On March 14, 2024, the Company issued a press release regarding some of its financial results for the fiscal year ended December 31, 2023; complete financial results for the fiscal year ended December 31, 2023 are included in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 13, 2024 . A copy of the press release is filed hereto as Exhibit 99.1, and is incorporated herein by reference. The information reported under this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Neither this Current Report on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company's securities in any state in which such an offer, solicitation or sale would be unlawful. The securities mentioned herein have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws.

01 Exhibits

Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File, formatted in Inline XBRL 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. March 14, 2024 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR